Clinical trials
Phase 2 Study clinical trials
Below are recruiting phase 2 study clinical trials, each written for real people, not researchers. We’re tracking 1,327 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07029529RecruitingPhase 2
Apremilast for alcohol use disorder
This study tests whether a drug called apremilast can help people who drink heavily reduce their alcohol use. You will take the medication daily for several weeks and attend study visits to track your progress.
New Haven, ConnecticutAges 21–65 - NCT07018570RecruitingPhase 2
Chemo, immunotherapy, and radiation for stomach cancer before surgery
This trial tests a combination of chemotherapy (FLOT), an immunotherapy drug (pembrolizumab), and short-course radiation before surgery for gastroesophageal junction cancer. The goal is to see if this approach improves outcomes.
Kashiwa, ChibaAges 18 years+ - NCT07005154RecruitingPhase 2
Study of ASP5541 for metastatic prostate cancer
This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.
Huntsville, AlabamaAges 18 years+ - NCT06990061Recruiting
Radiation therapy for BCG-resistant bladder CIS
This trial tests radiotherapy (high-energy X-rays) for a specific type of early-stage bladder cancer (CIS) that hasn't gone away after BCG treatment. It's for people who can't or choose not to have bladder removal surgery.
Anderlecht, Brussels CapitalAges 18 years+ - NCT06989359RecruitingPhase 2
Study of ADX-038 for complement-related kidney disease
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
Doral, FloridaAges 18 years+ - NCT06982963RecruitingPhase 2
Study of an experimental drug for celiac disease
This study tests an experimental medication for adults with celiac disease to see if it can protect against gluten exposure. You will need to follow a gluten-free diet and undergo a short, planned gluten challenge.
MelbourneAges 18–70 - NCT06990269RecruitingPhase 2
Study of ADX-038 for geographic atrophy in dry AMD
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
Gilbert, ArizonaAges 60 years+ - NCT06986174RecruitingPhase 2
Pacritinib for relapsed or refractory Waldenström macroglobulinemia
This trial tests a pill called pacritinib for people with Waldenström macroglobulinemia that has come back or stopped responding to other treatments. The goal is to see if pacritinib can help control the disease by blocking certain proteins that cancer cells need to grow.
Boston, MassachusettsAges 18 years+ - NCT06925984Recruiting
Targeted radiation for breast cancer that has spread and is growing a little
This trial tests whether giving focused, high-dose radiation to spots where the cancer is growing can help control the disease while you stay on your current hormone therapy and/or CDK4/6 inhibitor. It is for people with ER+/HER2- breast cancer that has spread to a few places and is slowly starting to progress.
BrusselsAges 18 years+ - NCT06885385RecruitingPhase 2
Study of JS207 with or without JS015 and chemo for colorectal cancer
This trial tests a new drug combination (JS207 with or without JS015) along with chemotherapy for people with advanced colorectal cancer that has not spread to other parts of the body. It aims to see if the treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06890039RecruitingPhase 2
Study of a new treatment for severe alcoholic hepatitis
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
London, Greater LondonAges 18–75 - NCT06859684RecruitingPhase 2
Triple therapy for advanced bile duct cancer of the liver
This trial tests a combination of three treatments for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The treatments include a chemotherapy infusion directly into the liver artery (HAIC), an immunotherapy drug (durvalumab), and a targeted therapy pill (lenvatinib). It aims to see if this triple therapy can shrink or control the cancer better than standard treatments.
Chengdu, SichuanAges 18–75 - NCT06854653RecruitingPhase 2
PTX 100 for relapsed CTCL
This trial tests an experimental drug called PTX 100 for people with cutaneous T-cell lymphoma (CTCL) that has come back after at least two prior treatments. It aims to see if PTX 100 can help shrink tumors or slow the disease.
Duarte, CaliforniaAges 18 years+ - NCT06854003RecruitingPhase 2
Study of new drug combo for untreated mantle cell lymphoma
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
Phoenix, ArizonaAges 18 years+ - NCT06830629RecruitingPhase 2
MZE829 for APOL1 kidney disease
This trial tests an experimental drug called MZE829 for people with kidney disease linked to the APOL1 gene. It aims to see if the drug can help protect kidney function.
Decatur, AlabamaAges 18–68 - NCT06822543RecruitingPhase 2
A new treatment for lung cancer that has spread to the brain
This trial tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) for people with a type of lung cancer called non-small cell lung cancer (NSCLC) that has spread to the brain and has not been treated before. The goal is to see if this combination can shrink tumors in the brain and elsewhere.
Fortaleza, CearáAges 18 years+ - NCT06789913RecruitingPhase 2
Testing RLY-2608 for growth disorders linked to PIK3CA mutations
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
Phoenix, ArizonaAges 2 years+ - NCT06786234RecruitingPhase 2
STP938 for high-risk essential thrombocythemia
This trial tests a daily pill called STP938 (dencatistat) for people with high-risk essential thrombocythemia (ET) who cannot take or have stopped responding to hydroxycarbamide. The goal is to see if STP938 can safely lower your platelet count and control the condition.
Poitiers, New AquitaineAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06680830RecruitingPhase 2
Testing NEU-411 for early Parkinson's with LRRK2 gene change
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
Sun City, ArizonaAges 40–80 - NCT06658899RecruitingPhase 2
Study of CRD-4730 for CPVT (rare heart rhythm disorder)
This study tests an experimental drug called CRD-4730 for people with CPVT, a rare inherited heart rhythm disorder that can cause dangerous fast heartbeats during exercise or stress. The trial will see if the drug can help control these abnormal heart rhythms better than current treatments.
San Francisco, CaliforniaAges 18–99 - NCT06627738RecruitingPhase 2
Extra radiation boost for advanced lung cancer after standard treatment
This trial tests whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can improve outcomes for people with stage III non-small cell lung cancer that cannot be surgically removed. It is for those who have already completed two cycles of induction chemo and at least 40 Gy of radiation with chemo.
NiceAges 18 years+ - NCT06589440RecruitingPhase 2
Study of SR-8541A plus two immunotherapies for advanced colorectal cancer
This trial tests a new drug combination (SR-8541A, botensilimab, and balstilimab) for people with a specific type of metastatic colorectal cancer that is not MSI-high. It aims to see if this combination can help when other treatments have stopped working.
Morristown, New JerseyAges 18 years+ - NCT06592274RecruitingPhase 2
Study of HB0017 for people with plaque psoriasis
This trial tests an investigational drug, HB0017, in adults with moderate to severe plaque psoriasis. If you have had psoriasis for at least 6 months and have not used certain biologic treatments, you may be able to join.
Bengbu, AnhuiAges 18–75
Hear when a new Phase 2 Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2 study?
- Yes. Clin2 currently lists 1,327 recruiting phase 2 study studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 study trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 study trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.